Clinical trials: Positive E Coli Infections
Anthrax
A New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at…
- Trial name
- NCT00057525
- Testing
- Anthrax, Alhdryogel or PBS
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- DynPort Vaccine Company LLC, A GDIT Company
Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E.
- Trial name
- E-Trike (NCT07106944)
- Testing
- Community pregnant women: rectal and throat swab
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
Drug Resistance, Microbial
Quinolone Resistance Profiles and Mechanisms of Staphylococcus Aureus and Escherichia Coli From Humans, Chicken and Catfish Farms in Indonesia
The goal of this observational study is to reveal quinolone resistance profiles and mechanisms in S. aureus and E. coli in the human, animal and aquaculture sector in Blitar, Indonesia.
- Trial name
- QUINDO (NCT05652556)
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Erasmus Medical Center
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Gastrointestinal Diseases, Foodborne Diseases
Health Impacts of Street Vended Fruits
This study will employ a randomized controlled intervention design to evaluate the health impacts of consuming fresh-cut street-vended fruits, focusing on microbial contamination and gastrointestinal (GI) symptoms.
- Conditions
- Gastrointestinal Diseases, Foodborne Diseases, Microbial Contamination, Street Vended Foods
- Trial name
- HISVF (NCT06858046)
- Testing
- Fresh-Cut Guava Consumption, Fresh-Cut Pineapple Consumption, Fresh-Cut Watermelon Consumption
- Where
- Bangladesh
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Bangladesh Agricultural University
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
This is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF)…
- Conditions
- CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections, Staphylococcus Aureus Infection
- Trial name
- NCT07280598
- Testing
- Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Bacterial Infections
Quinolone Resistance in Bloodstream Isolates of Escherichia Coli
This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of E. coli. Additionally, the adequacy of empiric antibiotic therapy for E. coli bloodstream infections will be assessed.
- Trial name
- NCT00449735
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Pittsburgh
Positive E Coli Infections
Ampicillin-sulbactam Resistant E.Coli at UPMC
The information collected will optimize the management of patients with gram negative bacteremia. Approximately 300 patients with Gram negative bacteremia are cared for each year at UPMC-P.
- Trial name
- NCT00619580
- Where
- United States
- Sponsor
- University of Pittsburgh
Escherichia Coli Infections, Staphylococcus Aureus
Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria
Our previous studies delineate a novel pathway of immune activation in animals that the investigators have named Anti-Virulence Immunity (AVI).
- Trial name
- NLRP3-Bact (NCT03869593)
- Testing
- Sample analysis
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Staphylococcus Aureus Infection
A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
This is an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group. The aim of the pilot study is to explore the preliminary safety of an experimental recombinant staphylococcus aureus…
- Trial name
- NCT02820883
- Testing
- Staphylococcus aureus vaccine (60µg/per protein), Staphylococcus aureus vaccine (30µg/per protein), Staphylococcus aureus vaccine (15µg/per protein)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Gram-Positive Bacterial Infections, Escherichia Coli Infections
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in…
- Conditions
- Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
- Trial name
- NCT00167999
- Testing
- piperacillin-tazobactam
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Staphylococcus Aureus Infection
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
This is a single center, open-label phase1b clinical trial. The study will evaluate the safety and immunogenicity of an experimental recombinant staphylococcus aureus vaccine with different immunization schedules in healthy…
- Trial name
- NCT03966040
- Testing
- Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7, Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Staphylococcus Aureus Infection
A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Before this study, there will be an open-label, dose-escalation pilot study with a total of 30 participants with 10 per dosage group.
- Trial name
- NCT02804711
- Testing
- Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml), Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml), High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Pneumonia, Bloodstream Infection
Clinical Outcomes in Patients With Infection by Resistant Microorganism
The goal of this individual patient data meta-analysis is to estimate the attributed and the associated health burden related to bloodstream infections, pneumonia, skin and soft tissue infections, surgical site infections and…
- Conditions
- Pneumonia, Bloodstream Infection, Urinary Tract Infections, Skin Infection
- Trial name
- NCT05880069
- Testing
- Pathogen resistant phenotype
- Where
- Spain
- Volunteers
- 5,000 people
- Sponsor
- Hospital Universitario Virgen Macarena